Pancreatic Cancer: Targeted Therapy Holds the Promise

Pancreatic cancer is one of the most lethal malignancies, with a 5-year overall survival rate of less than 10%, underpinning an unmet need for this devastating disease.1 Delineation of the molecular subtypes is prominent to better understanding of both the intertumoral and intratumoral heterogeneity in pancreatic cancer, and ultimately pave the way for precision oncology. Perturbed genomic integrity and transcriptomic reprogramming play important roles in tumorigenesis. Homologous recombination (HR) is one of the major DNA damage repair (DDR) pathways that are crucial to maintaining genomic integrity.